ABCL Stock Overview
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AbCellera Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.56 |
| 52 Week High | US$6.06 |
| 52 Week Low | US$2.40 |
| Beta | 0.39 |
| 11 Month Change | -21.47% |
| 3 Month Change | -34.69% |
| 1 Year Change | -54.20% |
| 33 Year Change | -86.34% |
| 5 Year Change | n/a |
| Change since IPO | -95.65% |
Recent News & Updates
Recent updates
AbCellera: A Waiting Game With High Uncertainty
Aug 23Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth
May 29
AbCellera: Cash Providing Shelter From Market Weakness
May 16AbCellera: Victim Of Its Own Success
Feb 28AbCellera Biologics: Continuing To Expand Partnerships
Feb 13Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?
Feb 04AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate
Nov 29AbCellera Biologics: Many Reasons To Own This Undervalued Stock
Sep 06AbCellera Biologics: COVID Antibody Set To Provide Continued Funding
Aug 14AbCellera partnering with Atlas Ventures on development of therapeutic antibodies
Aug 03AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying
Jun 06Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)
May 13Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%
May 07AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
Apr 22AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
Feb 11AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
Dec 05Shareholder Returns
| ABCL | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.9% | 0.7% | 0.06% |
| 1Y | -54.2% | 2.7% | 22.6% |
Return vs Industry: ABCL underperformed the US Life Sciences industry which returned 2.9% over the past year.
Return vs Market: ABCL underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 8.3% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABCL's share price has been volatile over the past 3 months.
Volatility Over Time: ABCL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 586 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
AbCellera Biologics Inc. Fundamentals Summary
| ABCL fundamental statistics | |
|---|---|
| Market cap | US$745.50m |
| Earnings (TTM) | -US$153.30m |
| Revenue (TTM) | US$33.05m |
22.8x
P/S Ratio-4.9x
P/E RatioIs ABCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABCL income statement (TTM) | |
|---|---|
| Revenue | US$33.05m |
| Cost of Revenue | US$166.75m |
| Gross Profit | -US$133.70m |
| Other Expenses | US$19.60m |
| Earnings | -US$153.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | -404.48% |
| Net Profit Margin | -463.79% |
| Debt/Equity Ratio | 0% |
How did ABCL perform over the long term?
See historical performance and comparison